Mr. Robert Kelly Hansen is a pharmacist who is specialized in Oncology in Layton, Utah. Patients can reach him at 514 Peregrine Cv, Layton or contact him on 801-510-5665. Active license number of Mr. Robert Kelly Hansen is 144957-1701 for Oncology in Utah. Mr. Robert Kelly Hansen is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Mr. Robert Kelly Hansen speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Mr. Robert Kelly Hansen
Specialization:
Oncology
Credentials:
RPH
Gender:
Male
Location:
514 Peregrine Cv, Layton, Utah, 84040-4514
Phone:
801-510-5665
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Mr. Robert Kelly Hansen are as mentioned below.
NPI Number:
1023191236
NPI Enumeration Date:
23 Oct, 2006
NPI Last Update On:
08 Jul, 2007
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Mr. Robert Kelly Hansen are as mentioned below.
Specialization
License Number
State
Status
Oncology
144957-1701
Utah
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
514 Peregrine Cv, Layton, Utah
Zip:
84040-4514
Phone Number:
801-510-5665
Fax Number:
--
Patients can reach Mr. Robert Kelly Hansen at 514 Peregrine Cv, Layton, Utah or can call on phone at 801-510-5665.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.